Question and Answer about Neurofilament Light Chain and Other MS Biomarkers
This program is supported by Novartis Pharmaceuticals Corporation. Content is independently developed by CMSC.
Mark Freedman, MD, MSc, Tanuja Chitnis, MD, and Ahmed Obeidat, MD, PhD, answer questions about biomarkers in MS care.
EP: 1.The Value of Biomarker in Multiple Sclerosis
EP: 2.Evolving Methods of Multiple Sclerosis Diagnosis
EP: 3.Assays to Detect Neurofilament Light
EP: 4.Challenges and Opportunity With MRI
EP: 5.Neurofilament Light Chain and Acute Gadolinium Enhancing Lesions
EP: 6.Exploring Potential Applications of Neurofilament Light Chain in MS Prognosis and Care
EP: 7.Practical Considerations for the Use of Neurofilament Light Chain and MRI
EP: 8.How to Address Increasing Neurofilament Light Chain Levels
EP: 9.Weighing Treatment Decisions Based on Neurofilament Light Chain Levels
EP: 10.Monitoring Patients After a Change in Treatment Regimen
EP: 11.Assessing Lesion Types With MS Biomarkers
EP: 12.Neurofilament Light Chain and MS Prognosis, Treatment Effect, and Anticipation of Disease
EP: 13.The CLIMB Study
EP: 14.Reimbursement for MRI
EP: 15.Understanding the Underlying Progression of Multiple Sclerosis
EP: 16.Biomarkers, Patient Communication, and the Future of Care
EP: 17.Question and Answer about Neurofilament Light Chain and Other MS Biomarkers
Experts discuss the approach to explaining NFL results to patients and their families. Experts emphasize the importance of clear communication, discussing the significance of the biomarker, and ensuring that patients understand the implications of the test results.
They describe the process of explaining NFL results to patients and their families. They focus on the need to provide context regarding why the test is conducted, what the results mean, and potential actions based on the outcomes. Ahmed Obeidat, MD, PhD, emphasizes the importance of a collaborative discussion, addressing lifestyle factors, medication adherence, and overall health. Ahmed Obeidat, MD, PhD, uses visual aids such as sketches to enhance patient understanding. Additionally, he mentions the challenge of patients sometimes receiving test results before the physician, highlighting the necessity of proactive communication. He touches on the idea of establishing reference values for individual patients, considering factors such as age and comorbidities, to better interpret NFL levels.
Video synopsis is AI-generated and reviewed by HCPLive® editorial staff.
